5:47 Immune TME Heterogeneity Revealed Via scRNA-seq August 4, 2021 • Oncology @preiszmd, of @sloan_kettering, discusses the use of #scRNA-seq to assess #heterogeneity in #UTUC.
10:04 Long-Term Follow-Up of POUT August 2, 2021 • Oncology Alison Birtle, MD, of @LancsHospitals, discusses updated results from the #POUT study, demonstrating increased #DFS with #chemo in #UTUC.
3:54 Immune Checkpoint Inhibitors in Upper and Lower Tract Urothelial Carcinoma August 2, 2021 • Oncology @PGrivasMDPhD, from @SeattleCCA @UWDeptMedicine @fredhutch, discusses outcomes of #ICI therapy in #UTUC vs LTUC.
14:10 Data Updates From ASCO 2021 August 2, 2021 • Oncology @amerseburger and @ERPlimackMD discuss data presented at #ASCO2021 on #urothelialcarcinoma.
1:49 Association Between Angiotensin Blockade and Response to PD-1/L1 Inhibition in Metastatic Urothelial Carcinoma August 1, 2021 • Oncology @sonpavde, of @DanaFarber_GU, discusses the effects of #angiotensin blockade on #PD-1/L1 inhibition in #metastatic #urothelialcarcinoma.
5:48 Therapeutic Effects of WST11 Vascular-Targeted Photodynamic Therapy August 1, 2021 • Urology @lucasmnnogueira, of @sloan_kettering, discusses the #safety and #efficacy of WST11 vascular-targeted #photodynamic therapy.
1:02 Updated Data From POUT Demonstrates Maintained Benefit July 1, 2021 • Oncology Robert Jones, MD, PhD, of @UofGlasgow, discusses #updates from the phase 3 #POUT study demonstrating #DFS benefit in #UTUC.
12:15 Case Discussion: 49-Year-Old Male With UTUC May 2, 2021 • Oncology @MattMossanen; @sonpavde; Steven L Chang, MD, MS; Michelle S. Hirsch, MD, PhD; and Mark A. Preston, MD, PhD, discuss a patient with #UTUC.
25:54 ASCO GU 2019: Updates on Treatment and Management of Bladder Cancer February 16, 2019 • Oncology
